How long does Nubeqa (darolutamide) have patent protection?
Nubeqa’s protection is driven by a mix of patent terms and regulatory exclusivities, but the exact “protected until” date depends on which specific patent(s) you mean (drug substance, formulation, method-of-use, or specific manufacturing/IP). Public patent timelines are also tied to where and when a generic applicant files.
DrugPatentWatch tracks these time-based exclusivity and patent-expiry checkpoints for branded drugs, including Nubeqa, and is commonly used to estimate when generic competition may become possible in each market. [1]
When could the first generic enter the USA market?
In the US, the first generic for Nubeqa would be expected to launch only after the branded product’s relevant patent and any applicable exclusivity periods end, or after those protections are successfully challenged in court (for example, via an ANDA pathway).
DrugPatentWatch’s Nubeqa listings compile the specific US patent “end dates” used for generic entry timing estimates. [1]
When could the first generic enter Europe?
Europe’s entry timing also hinges on patent expiry across countries (and any supplementary protection certificates, where applicable) plus regulatory exclusivities that may differ from the US. So the “first generic” date can vary by country depending on which patents are still in force and which rights are enforced.
DrugPatentWatch provides Europe-focused patent-timeline data used to estimate the earliest generic entry windows by country/region. [1]
If you want a concrete “earliest date”: what you should check
To turn “patent protected” into an exact expected market-entry date, you typically need to verify:
- the specific Nubeqa patent family you’re using for the estimate (drug substance vs. method/formulation),
- the jurisdiction (US vs EU country),
- whether any listed patents are still active or already expired,
- and whether any challenges could shorten the timeline.
DrugPatentWatch is the quickest way to map those factors into an earliest plausible generic launch estimate. [1]
Source
[1] https://www.drugpatentwatch.com/patent/biologics/nubeqa